CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 363-368

  Wang, Xin Feng ^a,b,c   Wu, Yan Hua ^c   Wang, Mao Shui ^c   Wang, Yun Shan ^a,b,d  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF JINAN   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^d JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Diagnosis; Discrimination; Malignant pleural effusion; Tumor markers; Unknown primary tumor

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST TUMOR; CHILD; FEMALE; HUMAN; LEUKEMIA; LUNG TUMOR; LYMPHOMA; MALE; MALIGNANT PLEURA EFFUSION; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BREAST NEOPLASMS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA; LUNG NEOPLASMS; LYMPHOMA; MALE; MESOTHELIOMA; MIDDLE AGED; MUCIN-1; PLEURAL EFFUSION, MALIGNANT; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84894026684     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.363     Document Type: Article

References (33)

1. Abbruzzese JL, Abbruzzese MC, Hess KR, et al (1994). Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol, 12, 1272-80.
2. Bocking A, Pomjansky N, Buckstegge B, et al (2009). Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies. Pathologe, 30, 158-60.
3. Bonnefoi H, Smith IE (1996). How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer, 74, 832-5.
4. Botte G, Laferrere L, Etchepare S, et al (1990). Diagnostic value of tumor markers in pleural effusions. Medicina, 50, 213-6.
5. Cascinu S, Del Ferro E, Barbanti I, et al (1997). Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol, 20, 247-50.
6. Cellerin L, Marcq M, Sagan C, et al (2008). Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers. Rev Mal Respir, 25, 1104-9.
7. Cheng M, Chen Y, Yu X, et al (2008). Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer, 8, 156.
8. Davidson B, Baekelandt M, Shih IeM (2007). MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol, 35, 756-60.
9. Destombe C, Botton E, Le Gal G, et al (2007). Investigations for bone metastasis from an unknown primary. Joint Bone Spine, 74, 85-9.
10. Elstrand MB, Kleinberg L, Kohn EC, et al (2009). Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol, 28, 211-21.
11. Gaspar MJ, De Miguel J, Garcia Diaz JD, et al (2008). Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res, 28, 2947-52.
12. Heffner JE, Nietert PJ, Barbieri C (2000). Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest, 117, 79-86.
13. Jiang B, Wu GP, Zhao YJ, et al (2008). Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol, 36, 849-54.
14. Kwee TC, Takahara T, Ochiai R, et al (2008). Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 18, 1937-52.
15. Kwee T C, Kwee RM (2009). Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol, 19, 731-44.
16. Liang QL, Shi HZ, Qin XJ, et al (2008). Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax, 63, 35-41.
17. Liu L, Cohen C, Siddiqui M T (2012). Thyroid transcription factor 1 and napsin a double staining in lung adenocarcinoma in pleural fluid. Acta Cytol, 56, 425-30.
18. Losa Gaspa F, Germa JR, Albareda JM, et al (2002). Metastatic cancer presentation. Validation of a diagnostic algorithm with 221 consecutive patients. Rev Clin Esp, 202, 313-9.
19. Malati T (2007). Tumour markers: An overview. Indian J Clin Biochem, 22, 17-31.
20. Panza N, Lombardi G, De Rosa M, et al (1987). High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer, 60, 2233-6.
21. Pavlidis N, Kalef-Ezra J, Briassoulis E, et al (1994). Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol, 22, 162-7.
22. Pavlidis N, Briasoulis E, Pentheroudakis G (2010). Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v228-31.
23. Pomjanski N, Grote HJ, Doganay P, et al (2005). Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol, 33, 309-15.
24. Porcel JM, Vives M, Esquerda A, et al (2004). Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest, 126, 1757-63.
25. Pu RT, Giordano TJ, Michael CW (2008). Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. Cancer, 114, 300-6.
26. Roberts ME, Neville E, Berrisford RG, et al (2010). Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 65, ii32-40.
27. Sears D, Hajdu SI (1987). The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol, 31, 85-97.
28. Shitrit D, Zingerman B, Shitrit AB, et al (2005). Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist, 10, 501-7.
29. SUN Yongchang, HU Hong, XIA Guoguang, XU Wenbing, WANG Hongwu (2011). An invesigation on diagnosis of pleural effusions in some teaching hospitals at Beijing district. Chin J Tube Resp Dise, 34, 233-.
30. Tsukushi S, Katagiri H, Kataoka T, et al (2006). Serum tumor markers in skeletal metastasis. Jpn J Clin Oncol, 36, 439-44.
31. van de Molengraft FJ, Vooijs GP (1989). Survival of patients with malignancy-associated effusions. Acta Cytol, 33, 911-6.
32. Watanabe N (1996). Organ specificity of tumor markers and its application for clinical diagnosis. Nihon Rinsho, 54, 1592-6.
33. Zhu W, Michael CW (2007). WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol, 35, 370-5.